Market Cap | 39.65M | P/E | - | EPS this Y | 44.10% | Ern Qtrly Grth | - |
Income | -30.19M | Forward P/E | -0.78 | EPS next Y | -15.20% | 50D Avg Chg | -9.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -12.00% |
Dividend | N/A | Price/Book | 0.68 | EPS next 5Y | - | 52W High Chg | -85.00% |
Recommedations | 1.70 | Quick Ratio | 3.85 | Shares Outstanding | 16.85M | 52W Low Chg | 89.00% |
Insider Own | 1.31% | ROA | -23.08% | Shares Float | 14.66M | Beta | 0.83 |
Inst Own | 20.52% | ROE | -87.32% | Shares Shorted/Prior | 301.81K/319.45K | Price | 2.76 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 193,987 | Target Price | 6.67 |
Oper. Margin | - | Earnings Date | Nov 11 | Volume | 119,504 | Change | -7.07% |
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
HC Wainwright & Co. | Buy | Aug 8, 24 |
HC Wainwright & Co. | Buy | May 15, 24 |
HC Wainwright & Co. | Buy | Apr 16, 24 |
Wedbush | Outperform | Nov 16, 23 |
HC Wainwright & Co. | Buy | Nov 14, 23 |
HC Wainwright & Co. | Buy | Aug 9, 23 |
Wedbush | Neutral | Jun 26, 23 |
Roth MKM | Buy | May 31, 23 |
Citigroup | Buy | May 26, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Ghosh Anirvan | Chief Executive Offi.. Chief Executive Officer | Jun 26 | Sell | 3.20 | 1,177 | 3,766 | 85,069 | 06/27/23 |
Ghosh Anirvan | Chief Executive Offi.. Chief Executive Officer | Jun 14 | Sell | 3.39 | 1,212 | 4,109 | 86,246 | 06/15/23 |
Ghosh Anirvan | Chief Executive Offi.. Chief Executive Officer | May 02 | Sell | 2.17 | 588 | 1,276 | 87,458 | 05/03/23 |
Dananberg Jamie | Chief Medical Office.. Chief Medical Officer | Mar 14 | Sell | 4.00 | 1,005 | 4,020 | 63,237 | 03/15/23 |
Ghosh Anirvan | Chief Executive Offi.. Chief Executive Officer | Sep 14 | Sell | 0.48 | 13,706 | 6,579 | 983,210 | 09/15/22 |
Dananberg Jamie | Chief Medical Office.. Chief Medical Officer | Sep 14 | Sell | 0.48 | 10,923 | 5,243 | 661,213 | 09/15/22 |
Ghosh Anirvan | Chief Executive Offi.. Chief Executive Officer | Aug 01 | Sell | 0.67 | 10,446 | 6,999 | 996,916 | 08/02/22 |
Dananberg Jamie | Chief Medical Office.. Chief Medical Officer | Jun 27 | Sell | 0.59 | 4,398 | 2,595 | 672,136 | 06/28/22 |
Ghosh Anirvan | Chief Executive Offi.. Chief Executive Officer | Jun 27 | Sell | 0.59 | 12,149 | 7,168 | 1,007,362 | 06/28/22 |
Dananberg Jamie | Chief Medical Office.. Chief Medical Officer | Jun 21 | Sell | 0.62 | 3,697 | 2,292 | 676,534 | 06/22/22 |